- Home
- QURE
QURE
uniQure N.V.
as 04-01-2025 4:00pm EST
| Founded: | 1998 | Country: | Netherlands |
| Employees: | N/A | City: | AMSTERDAM |
| Market Cap: | N/A | IPO Year: | 2007 |
| Target Price: | $38.22 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.92 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.73 - $19.18 | Next Earning Date: | 05-06-2025 |
| Revenue: | $27,119,000 | Revenue Growth: | 71.17% |
| Revenue Growth (this year): | 49.19% | Revenue Growth (next year): | 236.65% |
Stock Insider Trading Activity of uniQure N.V. (QURE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Abi-Saab Walid | QURE | Chief Medical Officer | Mar 3 '25 | Sell | $10.29 | 1,350 | $13,891.50 | 151,903 | |
| Potts Jeannette | QURE | Chief Legal Officer | Mar 3 '25 | Sell | $10.29 | 7,076 | $72,812.04 | 119,743 | |
| Kapusta Matthew C | QURE | CEO, Managing Director | Mar 3 '25 | Sell | $10.29 | 28,341 | $291,628.89 | 651,454 | |
| KLEMT CHRISTIAN | QURE | Chief Financial Officer | Mar 3 '25 | Sell | $10.29 | 10,438 | $107,407.02 | 217,730 | |
| Kapusta Matthew C | QURE | CEO, Managing Director | Feb 25 '25 | Sell | $11.01 | 33,444 | $362,015.34 | 651,454 | |
| KLEMT CHRISTIAN | QURE | Chief Financial Officer | Feb 25 '25 | Sell | $11.01 | 17,257 | $186,457.82 | 217,730 |
Latest uniQure N.V. News
QURE Breaking Stock News: Dive into QURE Ticker-Specific Updates for Smart Investing
MT Newswires
a month ago
Uniqure Insider Sold Shares Worth $291,629, According to a Recent SEC Filing
Simply Wall St.
a month ago
uniQure Full Year 2024 Earnings: Misses Expectations
Zacks
a month ago
UniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates
GlobeNewswire
a month ago
uniQure Announces 2024 Financial Results and Highlights Recent Company Progress
Simply Wall St.
a month ago
uniQure N.V. (NASDAQ:QURE) is a favorite amongst institutional investors who own 66%
Benzinga
2 months ago
uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years
PR Newswire
2 months ago
CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B
MT Newswires
2 months ago
UniQure Advances AMT-191 Trial in Fabry Disease
Compare QURE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "QURE uniQure N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.